Samardžić, Janko

Link to this page

Authority KeyName Variants
orcid::0000-0002-8464-4924
  • Samardžić, Janko (9)
Projects

Author's Bibliography

Prolonged Zaleplon Treatment Increases the Expression of Proteins Involved in GABAergic and Glutamatergic Signaling in the Rat Hippocampus

Martinović, Jelena; Samardžić, Janko; Zarić Kontić, Marina; Ivković, Sanja; Dacić, Sanja; Major, Tamara; Radosavljević, Milica; Švob Štrac, Dubravka

(MDPI, 2023)

TY  - JOUR
AU  - Martinović, Jelena
AU  - Samardžić, Janko
AU  - Zarić Kontić, Marina
AU  - Ivković, Sanja
AU  - Dacić, Sanja
AU  - Major, Tamara
AU  - Radosavljević, Milica
AU  - Švob Štrac, Dubravka
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5407
AB  - Zaleplon is a positive allosteric modulator of the γ-aminobutyric acid (GABA)A receptor approved for the short-term treatment of insomnia. Previous publications on zaleplon have not addressed the proteins involved in its mechanism of action but have mostly referred to behavioral or pharmacological studies. Since both GABAergic and glutamatergic signaling have been shown to regulate wakefulness and sleep, we examined the effects of prolonged zaleplon treatment (0.625 mg/kg for 5 days) on these systems in the hippocampus of male Wistar rats. Western blot and immunohistochemical analyses showed that the upregulated components of GABAergic signaling (glutamate decarboxylase, vesicular GABA transporter, GABA, and α1 subunit of the GABAA receptor) were accompanied by increased protein levels in the glutamatergic system (vesicular glutamate transporter 1 and NR1, NR2A, and NR2B subunits of N-methyl-d-aspartate receptor). Our results, showing that zaleplon enhances GABA neurotransmission in the hippocampus, were not surprising. However, we found that treatment also increased glutamatergic signaling. This could be the result of the downregulation of adenosine A1 receptors, important modulators of the glutamatergic system. Further studies are needed to investigate the effects of the zaleplon-induced increase in hippocampal glutamatergic neurotransmission and the possible involvement of the adenosine system in zaleplon’s mechanism of action.
PB  - MDPI
T2  - Brain Sciences
T1  - Prolonged Zaleplon Treatment Increases the Expression of Proteins Involved in GABAergic and Glutamatergic Signaling in the Rat Hippocampus
VL  - 13
IS  - 12
DO  - 10.3390/brainsci13121707
ER  - 
@article{
author = "Martinović, Jelena and Samardžić, Janko and Zarić Kontić, Marina and Ivković, Sanja and Dacić, Sanja and Major, Tamara and Radosavljević, Milica and Švob Štrac, Dubravka",
year = "2023",
abstract = "Zaleplon is a positive allosteric modulator of the γ-aminobutyric acid (GABA)A receptor approved for the short-term treatment of insomnia. Previous publications on zaleplon have not addressed the proteins involved in its mechanism of action but have mostly referred to behavioral or pharmacological studies. Since both GABAergic and glutamatergic signaling have been shown to regulate wakefulness and sleep, we examined the effects of prolonged zaleplon treatment (0.625 mg/kg for 5 days) on these systems in the hippocampus of male Wistar rats. Western blot and immunohistochemical analyses showed that the upregulated components of GABAergic signaling (glutamate decarboxylase, vesicular GABA transporter, GABA, and α1 subunit of the GABAA receptor) were accompanied by increased protein levels in the glutamatergic system (vesicular glutamate transporter 1 and NR1, NR2A, and NR2B subunits of N-methyl-d-aspartate receptor). Our results, showing that zaleplon enhances GABA neurotransmission in the hippocampus, were not surprising. However, we found that treatment also increased glutamatergic signaling. This could be the result of the downregulation of adenosine A1 receptors, important modulators of the glutamatergic system. Further studies are needed to investigate the effects of the zaleplon-induced increase in hippocampal glutamatergic neurotransmission and the possible involvement of the adenosine system in zaleplon’s mechanism of action.",
publisher = "MDPI",
journal = "Brain Sciences",
title = "Prolonged Zaleplon Treatment Increases the Expression of Proteins Involved in GABAergic and Glutamatergic Signaling in the Rat Hippocampus",
volume = "13",
number = "12",
doi = "10.3390/brainsci13121707"
}
Martinović, J., Samardžić, J., Zarić Kontić, M., Ivković, S., Dacić, S., Major, T., Radosavljević, M.,& Švob Štrac, D.. (2023). Prolonged Zaleplon Treatment Increases the Expression of Proteins Involved in GABAergic and Glutamatergic Signaling in the Rat Hippocampus. in Brain Sciences
MDPI., 13(12).
https://doi.org/10.3390/brainsci13121707
Martinović J, Samardžić J, Zarić Kontić M, Ivković S, Dacić S, Major T, Radosavljević M, Švob Štrac D. Prolonged Zaleplon Treatment Increases the Expression of Proteins Involved in GABAergic and Glutamatergic Signaling in the Rat Hippocampus. in Brain Sciences. 2023;13(12).
doi:10.3390/brainsci13121707 .
Martinović, Jelena, Samardžić, Janko, Zarić Kontić, Marina, Ivković, Sanja, Dacić, Sanja, Major, Tamara, Radosavljević, Milica, Švob Štrac, Dubravka, "Prolonged Zaleplon Treatment Increases the Expression of Proteins Involved in GABAergic and Glutamatergic Signaling in the Rat Hippocampus" in Brain Sciences, 13, no. 12 (2023),
https://doi.org/10.3390/brainsci13121707 . .

Quantification of Zonisamide in Dried Blood Spots and Dried Plasma Spots by UPLC–MS/MS: Application to Clinical Practice

Rmandić, Milena; Stajić, Ana; Jančić, Jasna; Samardžić, Janko; Jović, Nebojša; Malenović, Anđelija

(MDPI, 2022)

TY  - JOUR
AU  - Rmandić, Milena
AU  - Stajić, Ana
AU  - Jančić, Jasna
AU  - Samardžić, Janko
AU  - Jović, Nebojša
AU  - Malenović, Anđelija
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4262
AB  - In this research, a UHPLC–MS/MS method was developed and validated for the deter-
mination of zonisamide in dried plasma spots (DPS) and dried blood spots (DBS). Detection of
zonisamide and internal standard, 1-(2,3-dichlorphenyl)piperazine, was carried out in ESI+ mode by
monitoring two MRM transitions per analyte. Total run time, less than 2.5 min, was achieved using
Acquity UPLC BEH Amide (2.1 × 100 mm, 1.7 μm particle size) column with mobile phase com-
prising acetonitrile–water (85:15%, v/v) with 0.075% formic acid. The flow rate was 0.225 mL/min,
the column temperature was 30 ◦C and the injection volume was 3 μL. Desolvation temperature,
desolvation gas flow rate, ion source temperature and cone gas flow rate were set by the IntelliStart
software tool in combination with tuning. All of the Guthrie cards were scanned, and DPS/DBS
areas were determined by the image processing tool. The influence of hematocrit values (20–60%)
on accuracy and precision was evaluated to determine the range within which method for DBSs is
free from Hct or dependency is within acceptable limits. The validated method was applied to the
determination of zonisamide levels in DPS and DBS samples obtained from patients confirming its
suitability for clinical application. Finally, the distribution of zonisamide into the red blood cells was
estimated by correlating its DPS and DBS levels.
PB  - MDPI
T2  - Molecules
T1  - Quantification of Zonisamide in Dried Blood Spots and Dried Plasma Spots by UPLC–MS/MS: Application to Clinical Practice
VL  - 27
IS  - 15
DO  - 10.3390/molecules27154899
ER  - 
@article{
author = "Rmandić, Milena and Stajić, Ana and Jančić, Jasna and Samardžić, Janko and Jović, Nebojša and Malenović, Anđelija",
year = "2022",
abstract = "In this research, a UHPLC–MS/MS method was developed and validated for the deter-
mination of zonisamide in dried plasma spots (DPS) and dried blood spots (DBS). Detection of
zonisamide and internal standard, 1-(2,3-dichlorphenyl)piperazine, was carried out in ESI+ mode by
monitoring two MRM transitions per analyte. Total run time, less than 2.5 min, was achieved using
Acquity UPLC BEH Amide (2.1 × 100 mm, 1.7 μm particle size) column with mobile phase com-
prising acetonitrile–water (85:15%, v/v) with 0.075% formic acid. The flow rate was 0.225 mL/min,
the column temperature was 30 ◦C and the injection volume was 3 μL. Desolvation temperature,
desolvation gas flow rate, ion source temperature and cone gas flow rate were set by the IntelliStart
software tool in combination with tuning. All of the Guthrie cards were scanned, and DPS/DBS
areas were determined by the image processing tool. The influence of hematocrit values (20–60%)
on accuracy and precision was evaluated to determine the range within which method for DBSs is
free from Hct or dependency is within acceptable limits. The validated method was applied to the
determination of zonisamide levels in DPS and DBS samples obtained from patients confirming its
suitability for clinical application. Finally, the distribution of zonisamide into the red blood cells was
estimated by correlating its DPS and DBS levels.",
publisher = "MDPI",
journal = "Molecules",
title = "Quantification of Zonisamide in Dried Blood Spots and Dried Plasma Spots by UPLC–MS/MS: Application to Clinical Practice",
volume = "27",
number = "15",
doi = "10.3390/molecules27154899"
}
Rmandić, M., Stajić, A., Jančić, J., Samardžić, J., Jović, N.,& Malenović, A.. (2022). Quantification of Zonisamide in Dried Blood Spots and Dried Plasma Spots by UPLC–MS/MS: Application to Clinical Practice. in Molecules
MDPI., 27(15).
https://doi.org/10.3390/molecules27154899
Rmandić M, Stajić A, Jančić J, Samardžić J, Jović N, Malenović A. Quantification of Zonisamide in Dried Blood Spots and Dried Plasma Spots by UPLC–MS/MS: Application to Clinical Practice. in Molecules. 2022;27(15).
doi:10.3390/molecules27154899 .
Rmandić, Milena, Stajić, Ana, Jančić, Jasna, Samardžić, Janko, Jović, Nebojša, Malenović, Anđelija, "Quantification of Zonisamide in Dried Blood Spots and Dried Plasma Spots by UPLC–MS/MS: Application to Clinical Practice" in Molecules, 27, no. 15 (2022),
https://doi.org/10.3390/molecules27154899 . .
1
3
3

Acute effects of an inverse agonist selective for alpha(5) GABA(A) receptors on rat behaviour in the forced swim test

Samardžić, Janko; Batinić, Bojan; Biawat, Poonam; Obradović, Dragan I.; Cook, James M.; Savić, Miroslav

(Elsevier Science BV, Amsterdam, 2012)

TY  - CONF
AU  - Samardžić, Janko
AU  - Batinić, Bojan
AU  - Biawat, Poonam
AU  - Obradović, Dragan I.
AU  - Cook, James M.
AU  - Savić, Miroslav
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1662
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Acute effects of an inverse agonist selective for alpha(5) GABA(A) receptors on rat behaviour in the forced swim test
VL  - 22
IS  - Supplement 2
SP  - S187
EP  - S188
DO  - 10.1016/S0924-977X(12)70269-9
ER  - 
@conference{
author = "Samardžić, Janko and Batinić, Bojan and Biawat, Poonam and Obradović, Dragan I. and Cook, James M. and Savić, Miroslav",
year = "2012",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Acute effects of an inverse agonist selective for alpha(5) GABA(A) receptors on rat behaviour in the forced swim test",
volume = "22",
number = "Supplement 2",
pages = "S187-S188",
doi = "10.1016/S0924-977X(12)70269-9"
}
Samardžić, J., Batinić, B., Biawat, P., Obradović, D. I., Cook, J. M.,& Savić, M.. (2012). Acute effects of an inverse agonist selective for alpha(5) GABA(A) receptors on rat behaviour in the forced swim test. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 22(Supplement 2), S187-S188.
https://doi.org/10.1016/S0924-977X(12)70269-9
Samardžić J, Batinić B, Biawat P, Obradović DI, Cook JM, Savić M. Acute effects of an inverse agonist selective for alpha(5) GABA(A) receptors on rat behaviour in the forced swim test. in European Neuropsychopharmacology. 2012;22(Supplement 2):S187-S188.
doi:10.1016/S0924-977X(12)70269-9 .
Samardžić, Janko, Batinić, Bojan, Biawat, Poonam, Obradović, Dragan I., Cook, James M., Savić, Miroslav, "Acute effects of an inverse agonist selective for alpha(5) GABA(A) receptors on rat behaviour in the forced swim test" in European Neuropsychopharmacology, 22, no. Supplement 2 (2012):S187-S188,
https://doi.org/10.1016/S0924-977X(12)70269-9 . .

Midazolam impairs acquisition but not consolidation in water maze paradigm

Milinković, Marija M.; Samardžić, Janko; Divljaković, Jovana; Joksimović, Srđan; Timić, Tamara; Savić, Miroslav

(Elsevier Science BV, Amsterdam, 2010)

TY  - CONF
AU  - Milinković, Marija M.
AU  - Samardžić, Janko
AU  - Divljaković, Jovana
AU  - Joksimović, Srđan
AU  - Timić, Tamara
AU  - Savić, Miroslav
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1347
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Midazolam impairs acquisition but not consolidation in water maze paradigm
VL  - 20
IS  - Supplement 3
SP  - S259
EP  - S260
DO  - 10.1016/S0924-977X(10)70330-8
ER  - 
@conference{
author = "Milinković, Marija M. and Samardžić, Janko and Divljaković, Jovana and Joksimović, Srđan and Timić, Tamara and Savić, Miroslav",
year = "2010",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Midazolam impairs acquisition but not consolidation in water maze paradigm",
volume = "20",
number = "Supplement 3",
pages = "S259-S260",
doi = "10.1016/S0924-977X(10)70330-8"
}
Milinković, M. M., Samardžić, J., Divljaković, J., Joksimović, S., Timić, T.,& Savić, M.. (2010). Midazolam impairs acquisition but not consolidation in water maze paradigm. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 20(Supplement 3), S259-S260.
https://doi.org/10.1016/S0924-977X(10)70330-8
Milinković MM, Samardžić J, Divljaković J, Joksimović S, Timić T, Savić M. Midazolam impairs acquisition but not consolidation in water maze paradigm. in European Neuropsychopharmacology. 2010;20(Supplement 3):S259-S260.
doi:10.1016/S0924-977X(10)70330-8 .
Milinković, Marija M., Samardžić, Janko, Divljaković, Jovana, Joksimović, Srđan, Timić, Tamara, Savić, Miroslav, "Midazolam impairs acquisition but not consolidation in water maze paradigm" in European Neuropsychopharmacology, 20, no. Supplement 3 (2010):S259-S260,
https://doi.org/10.1016/S0924-977X(10)70330-8 . .

Jy-xhe-053, a benzodiazepine ligand less efficacious at GABAA receptors containing alpha1 and alpha5 than alpha2 and alpha3 subunits

Milinković, Marija M.; Savić, Miroslav; Huang, Shengming; Furtmueller, Roman; Majumder, Samarpan; Samardžić, Janko; Divljaković, Jovana; Roth, Brian L.; Sieghart, Werner; Cook, James M.

(Elsevier Science BV, Amsterdam, 2009)

TY  - CONF
AU  - Milinković, Marija M.
AU  - Savić, Miroslav
AU  - Huang, Shengming
AU  - Furtmueller, Roman
AU  - Majumder, Samarpan
AU  - Samardžić, Janko
AU  - Divljaković, Jovana
AU  - Roth, Brian L.
AU  - Sieghart, Werner
AU  - Cook, James M.
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1173
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Jy-xhe-053, a benzodiazepine ligand less efficacious at GABAA receptors containing alpha1 and alpha5 than alpha2 and alpha3 subunits
VL  - 19
IS  - Supplement 3
SP  - S296
EP  - S296
DO  - 10.1016/S0924-977X(09)70438-9
ER  - 
@conference{
author = "Milinković, Marija M. and Savić, Miroslav and Huang, Shengming and Furtmueller, Roman and Majumder, Samarpan and Samardžić, Janko and Divljaković, Jovana and Roth, Brian L. and Sieghart, Werner and Cook, James M.",
year = "2009",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Jy-xhe-053, a benzodiazepine ligand less efficacious at GABAA receptors containing alpha1 and alpha5 than alpha2 and alpha3 subunits",
volume = "19",
number = "Supplement 3",
pages = "S296-S296",
doi = "10.1016/S0924-977X(09)70438-9"
}
Milinković, M. M., Savić, M., Huang, S., Furtmueller, R., Majumder, S., Samardžić, J., Divljaković, J., Roth, B. L., Sieghart, W.,& Cook, J. M.. (2009). Jy-xhe-053, a benzodiazepine ligand less efficacious at GABAA receptors containing alpha1 and alpha5 than alpha2 and alpha3 subunits. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 19(Supplement 3), S296-S296.
https://doi.org/10.1016/S0924-977X(09)70438-9
Milinković MM, Savić M, Huang S, Furtmueller R, Majumder S, Samardžić J, Divljaković J, Roth BL, Sieghart W, Cook JM. Jy-xhe-053, a benzodiazepine ligand less efficacious at GABAA receptors containing alpha1 and alpha5 than alpha2 and alpha3 subunits. in European Neuropsychopharmacology. 2009;19(Supplement 3):S296-S296.
doi:10.1016/S0924-977X(09)70438-9 .
Milinković, Marija M., Savić, Miroslav, Huang, Shengming, Furtmueller, Roman, Majumder, Samarpan, Samardžić, Janko, Divljaković, Jovana, Roth, Brian L., Sieghart, Werner, Cook, James M., "Jy-xhe-053, a benzodiazepine ligand less efficacious at GABAA receptors containing alpha1 and alpha5 than alpha2 and alpha3 subunits" in European Neuropsychopharmacology, 19, no. Supplement 3 (2009):S296-S296,
https://doi.org/10.1016/S0924-977X(09)70438-9 . .

RY-023, an inverse agonist at alpha5 GABAA receptors: the influence on spatial memory and spontaneous locomotor activity

Milinković, Marija M.; Savić, Miroslav; Rallapalli, Sundari; Samardžić, Janko; van Linn, Michael; Ugrešić, Nenad; Cook, James M.

(Elsevier Science BV, Amsterdam, 2008)

TY  - CONF
AU  - Milinković, Marija M.
AU  - Savić, Miroslav
AU  - Rallapalli, Sundari
AU  - Samardžić, Janko
AU  - van Linn, Michael
AU  - Ugrešić, Nenad
AU  - Cook, James M.
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1063
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - RY-023, an inverse agonist at alpha5 GABAA receptors: the influence on spatial memory and spontaneous locomotor activity
VL  - 18
IS  - Supplement 4
SP  - S284
EP  - S284
DO  - 10.1016/S0924-977X(08)70375-4
ER  - 
@conference{
author = "Milinković, Marija M. and Savić, Miroslav and Rallapalli, Sundari and Samardžić, Janko and van Linn, Michael and Ugrešić, Nenad and Cook, James M.",
year = "2008",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "RY-023, an inverse agonist at alpha5 GABAA receptors: the influence on spatial memory and spontaneous locomotor activity",
volume = "18",
number = "Supplement 4",
pages = "S284-S284",
doi = "10.1016/S0924-977X(08)70375-4"
}
Milinković, M. M., Savić, M., Rallapalli, S., Samardžić, J., van Linn, M., Ugrešić, N.,& Cook, J. M.. (2008). RY-023, an inverse agonist at alpha5 GABAA receptors: the influence on spatial memory and spontaneous locomotor activity. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 18(Supplement 4), S284-S284.
https://doi.org/10.1016/S0924-977X(08)70375-4
Milinković MM, Savić M, Rallapalli S, Samardžić J, van Linn M, Ugrešić N, Cook JM. RY-023, an inverse agonist at alpha5 GABAA receptors: the influence on spatial memory and spontaneous locomotor activity. in European Neuropsychopharmacology. 2008;18(Supplement 4):S284-S284.
doi:10.1016/S0924-977X(08)70375-4 .
Milinković, Marija M., Savić, Miroslav, Rallapalli, Sundari, Samardžić, Janko, van Linn, Michael, Ugrešić, Nenad, Cook, James M., "RY-023, an inverse agonist at alpha5 GABAA receptors: the influence on spatial memory and spontaneous locomotor activity" in European Neuropsychopharmacology, 18, no. Supplement 4 (2008):S284-S284,
https://doi.org/10.1016/S0924-977X(08)70375-4 . .

Effects of a novel inverse agonist selective for alpha5 GABAA receptors on spatial memory: comparison with the standard non-selective inverse agonist DMCM

Samardžić, Janko; Savić, Miroslav; Clayton, Terry; Rallapalli, Sundari; Obradović, Dragan I.; Joksimović, Srđan; Sieghart, Werner; Cook, James M.

(Elsevier Science BV, Amsterdam, 2008)

TY  - CONF
AU  - Samardžić, Janko
AU  - Savić, Miroslav
AU  - Clayton, Terry
AU  - Rallapalli, Sundari
AU  - Obradović, Dragan I.
AU  - Joksimović, Srđan
AU  - Sieghart, Werner
AU  - Cook, James M.
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1025
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Effects of a novel inverse agonist selective for alpha5 GABAA receptors on spatial memory: comparison with the standard non-selective inverse agonist DMCM
VL  - 18
IS  - Supplement 4
SP  - S285
EP  - S285
DO  - 10.1016/S0924-977X(08)70377-8
ER  - 
@conference{
author = "Samardžić, Janko and Savić, Miroslav and Clayton, Terry and Rallapalli, Sundari and Obradović, Dragan I. and Joksimović, Srđan and Sieghart, Werner and Cook, James M.",
year = "2008",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Effects of a novel inverse agonist selective for alpha5 GABAA receptors on spatial memory: comparison with the standard non-selective inverse agonist DMCM",
volume = "18",
number = "Supplement 4",
pages = "S285-S285",
doi = "10.1016/S0924-977X(08)70377-8"
}
Samardžić, J., Savić, M., Clayton, T., Rallapalli, S., Obradović, D. I., Joksimović, S., Sieghart, W.,& Cook, J. M.. (2008). Effects of a novel inverse agonist selective for alpha5 GABAA receptors on spatial memory: comparison with the standard non-selective inverse agonist DMCM. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 18(Supplement 4), S285-S285.
https://doi.org/10.1016/S0924-977X(08)70377-8
Samardžić J, Savić M, Clayton T, Rallapalli S, Obradović DI, Joksimović S, Sieghart W, Cook JM. Effects of a novel inverse agonist selective for alpha5 GABAA receptors on spatial memory: comparison with the standard non-selective inverse agonist DMCM. in European Neuropsychopharmacology. 2008;18(Supplement 4):S285-S285.
doi:10.1016/S0924-977X(08)70377-8 .
Samardžić, Janko, Savić, Miroslav, Clayton, Terry, Rallapalli, Sundari, Obradović, Dragan I., Joksimović, Srđan, Sieghart, Werner, Cook, James M., "Effects of a novel inverse agonist selective for alpha5 GABAA receptors on spatial memory: comparison with the standard non-selective inverse agonist DMCM" in European Neuropsychopharmacology, 18, no. Supplement 4 (2008):S285-S285,
https://doi.org/10.1016/S0924-977X(08)70377-8 . .

Hypolocomotor activity of DIAZEPAM in wistar rats is mediated by Gabaa receptors containing the Alphal, but not the Alpha5 subunit

Savić, Miroslav; Rallapalli, Sundari; Milinković, Marija M.; Samardžić, Janko; van Linn, Michael; Cook, James M.

(Cambridge Univ Press, New York, 2008)

TY  - CONF
AU  - Savić, Miroslav
AU  - Rallapalli, Sundari
AU  - Milinković, Marija M.
AU  - Samardžić, Janko
AU  - van Linn, Michael
AU  - Cook, James M.
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1102
PB  - Cambridge Univ Press, New York
C3  - International Journal of Neuropsychopharmacology
T1  - Hypolocomotor activity of DIAZEPAM in wistar rats is mediated by Gabaa receptors containing the Alphal, but not the Alpha5 subunit
VL  - 11
SP  - 212
EP  - 212
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1102
ER  - 
@conference{
author = "Savić, Miroslav and Rallapalli, Sundari and Milinković, Marija M. and Samardžić, Janko and van Linn, Michael and Cook, James M.",
year = "2008",
publisher = "Cambridge Univ Press, New York",
journal = "International Journal of Neuropsychopharmacology",
title = "Hypolocomotor activity of DIAZEPAM in wistar rats is mediated by Gabaa receptors containing the Alphal, but not the Alpha5 subunit",
volume = "11",
pages = "212-212",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1102"
}
Savić, M., Rallapalli, S., Milinković, M. M., Samardžić, J., van Linn, M.,& Cook, J. M.. (2008). Hypolocomotor activity of DIAZEPAM in wistar rats is mediated by Gabaa receptors containing the Alphal, but not the Alpha5 subunit. in International Journal of Neuropsychopharmacology
Cambridge Univ Press, New York., 11, 212-212.
https://hdl.handle.net/21.15107/rcub_farfar_1102
Savić M, Rallapalli S, Milinković MM, Samardžić J, van Linn M, Cook JM. Hypolocomotor activity of DIAZEPAM in wistar rats is mediated by Gabaa receptors containing the Alphal, but not the Alpha5 subunit. in International Journal of Neuropsychopharmacology. 2008;11:212-212.
https://hdl.handle.net/21.15107/rcub_farfar_1102 .
Savić, Miroslav, Rallapalli, Sundari, Milinković, Marija M., Samardžić, Janko, van Linn, Michael, Cook, James M., "Hypolocomotor activity of DIAZEPAM in wistar rats is mediated by Gabaa receptors containing the Alphal, but not the Alpha5 subunit" in International Journal of Neuropsychopharmacology, 11 (2008):212-212,
https://hdl.handle.net/21.15107/rcub_farfar_1102 .

PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha 5 subunits, improves passive, but not active, avoidance learning in rats

Savić, Miroslav; Clayton, Terry; Furtmueller, Roman; Gaurilović, Ivana; Samardžić, Janko; Savić, Snežana; Huck, Sigismund; Sieghart, Werner; Cook, James M.

(Elsevier Science BV, Amsterdam, 2008)

TY  - JOUR
AU  - Savić, Miroslav
AU  - Clayton, Terry
AU  - Furtmueller, Roman
AU  - Gaurilović, Ivana
AU  - Samardžić, Janko
AU  - Savić, Snežana
AU  - Huck, Sigismund
AU  - Sieghart, Werner
AU  - Cook, James M.
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1081
AB  - Benzodiazepine (BZ) site ligands affect vigilance, anxiety, memory processes, muscle tone and epileptogenic propensity through modulation of neurotransmission at GABA(A) receptors containing alpha 1, alpha 2, alpha 3 or alpha 5 subunits, and may have numerous experimental and clinical applications. The ability of non-selective BZ site inverse agonists to enhance cognition, documented in animal models and human studies, is clinically not feasible due to potentially unacceptable psychomotor effects. Most investigations to date have proposed the alpha 1 and/or alpha 5 subunit-containing GABA(A) receptors as comprising the memory-modulating population of these receptors. The novel ligand PWZ-029, which we synthesized and characterized electrophysiologically, possesses in vitro binding selectivity and moderate inverse agonist functional selectivity at alpha 5-containing GABA(A) receptors. This ligand has also been examined in rats in the passive and active avoidance, spontaneous locomotor activity, elevated plus maze and grip strength tests, primarily predictive of the effects on the memory acquisition, basal locomotor activity, anxiety level and muscle tone, respectively. The improvement of task learning was detected at the dose of 5 mg/kg in the passive, but not active avoidance test. The inverse agonist PWZ-029 had no effect on anxiety or muscle tone, whereas at higher doses (10 and 20 mg/kg) it decreased locomotor activity. This effect was antagonized by flumazenil. and also by the lower (but not the higher) dose of an agonist (SH-053-R-CH3-2'F) selective for GABA(A) receptors containing the alpha 5 subunit. The hypolocomotor effect of PWZ-029 was not antagonized by the antagonist beta-CCt exhibiting a preferential affinity for alpha 1-subunit-containing receptors. These data suggest that moderate negative modulation at GABA(A) receptors containing the alpha 5 subunit is a sufficient condition for eliciting enhanced encoding/consolidation of declarative memory, while the influence of higher doses of modulators at these receptors on motor activity shows an intricate pattern whose relevance and mechanism await to be defined.
PB  - Elsevier Science BV, Amsterdam
T2  - Brain Research
T1  - PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha 5 subunits, improves passive, but not active, avoidance learning in rats
VL  - 1208
SP  - 150
EP  - 159
DO  - 10.1016/j.brainres.2008.02.020
ER  - 
@article{
author = "Savić, Miroslav and Clayton, Terry and Furtmueller, Roman and Gaurilović, Ivana and Samardžić, Janko and Savić, Snežana and Huck, Sigismund and Sieghart, Werner and Cook, James M.",
year = "2008",
abstract = "Benzodiazepine (BZ) site ligands affect vigilance, anxiety, memory processes, muscle tone and epileptogenic propensity through modulation of neurotransmission at GABA(A) receptors containing alpha 1, alpha 2, alpha 3 or alpha 5 subunits, and may have numerous experimental and clinical applications. The ability of non-selective BZ site inverse agonists to enhance cognition, documented in animal models and human studies, is clinically not feasible due to potentially unacceptable psychomotor effects. Most investigations to date have proposed the alpha 1 and/or alpha 5 subunit-containing GABA(A) receptors as comprising the memory-modulating population of these receptors. The novel ligand PWZ-029, which we synthesized and characterized electrophysiologically, possesses in vitro binding selectivity and moderate inverse agonist functional selectivity at alpha 5-containing GABA(A) receptors. This ligand has also been examined in rats in the passive and active avoidance, spontaneous locomotor activity, elevated plus maze and grip strength tests, primarily predictive of the effects on the memory acquisition, basal locomotor activity, anxiety level and muscle tone, respectively. The improvement of task learning was detected at the dose of 5 mg/kg in the passive, but not active avoidance test. The inverse agonist PWZ-029 had no effect on anxiety or muscle tone, whereas at higher doses (10 and 20 mg/kg) it decreased locomotor activity. This effect was antagonized by flumazenil. and also by the lower (but not the higher) dose of an agonist (SH-053-R-CH3-2'F) selective for GABA(A) receptors containing the alpha 5 subunit. The hypolocomotor effect of PWZ-029 was not antagonized by the antagonist beta-CCt exhibiting a preferential affinity for alpha 1-subunit-containing receptors. These data suggest that moderate negative modulation at GABA(A) receptors containing the alpha 5 subunit is a sufficient condition for eliciting enhanced encoding/consolidation of declarative memory, while the influence of higher doses of modulators at these receptors on motor activity shows an intricate pattern whose relevance and mechanism await to be defined.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "Brain Research",
title = "PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha 5 subunits, improves passive, but not active, avoidance learning in rats",
volume = "1208",
pages = "150-159",
doi = "10.1016/j.brainres.2008.02.020"
}
Savić, M., Clayton, T., Furtmueller, R., Gaurilović, I., Samardžić, J., Savić, S., Huck, S., Sieghart, W.,& Cook, J. M.. (2008). PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha 5 subunits, improves passive, but not active, avoidance learning in rats. in Brain Research
Elsevier Science BV, Amsterdam., 1208, 150-159.
https://doi.org/10.1016/j.brainres.2008.02.020
Savić M, Clayton T, Furtmueller R, Gaurilović I, Samardžić J, Savić S, Huck S, Sieghart W, Cook JM. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha 5 subunits, improves passive, but not active, avoidance learning in rats. in Brain Research. 2008;1208:150-159.
doi:10.1016/j.brainres.2008.02.020 .
Savić, Miroslav, Clayton, Terry, Furtmueller, Roman, Gaurilović, Ivana, Samardžić, Janko, Savić, Snežana, Huck, Sigismund, Sieghart, Werner, Cook, James M., "PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha 5 subunits, improves passive, but not active, avoidance learning in rats" in Brain Research, 1208 (2008):150-159,
https://doi.org/10.1016/j.brainres.2008.02.020 . .
9
47
54
51